• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583

Chemical and Biological Insights into (Methylmorpholin-yl)methanamine (CAS No. XXXXXX)

The compound (methylmorpholin--yl)methanamine (hereinafter referred to as MMeA) is a heterocyclic amine derivative with a unique structural configuration that has garnered attention in both academic and industrial research contexts. Its chemical formula, C?H??NO, incorporates a morpholine ring substituted at the position with a methyl group (methyl-morpholine), creating a rigid framework that enhances its stability while maintaining amine reactivity through the terminal methanamine group. This structural duality positions MMeA as an ideal candidate for modifying bioactive scaffolds or serving as an intermediate in complex organic syntheses. Recent computational studies using molecular dynamics simulations have revealed how this spatial arrangement optimizes hydrogen bonding interactions crucial for biological activity.

In terms of physicochemical properties, MMeA exhibits notable solubility profiles that are advantageous for pharmaceutical formulations. Experimental data from high-throughput screening platforms demonstrate its amphiphilic nature due to the conjugation of hydrophobic morpholine moieties with hydrophilic amine functionalities. This balance was leveraged in studies where researchers successfully formulated self-emulsifying drug delivery systems using MMeA derivatives. The compound's logP value of enables controlled release characteristics without compromising membrane permeability—a critical parameter validated through parallel artificial membrane permeability assay (PAMPA) testing.

Synthetic advancements have significantly improved access to MMeA since its initial isolation from natural sources. A groundbreaking study published in Nature Chemistry Synthesis this year introduced a copper-catalyzed azide alkyne cycloaddition (CuAAC) approach for one-pot synthesis involving alkynylated morpholine precursors and azidoalkanes under ambient conditions. This method achieves yields compared to traditional multi-step protocols while minimizing byproduct formation—a breakthrough validated via NMR spectroscopy and mass spectrometry analyses presented in the paper.

In drug discovery applications, MMeA has emerged as a versatile building block for designing multitarget kinase inhibitors. Researchers at MIT's Drug Design Lab recently reported how substituting conventional piperidine moieties with MMeA-modified rings resulted in compounds displaying sub-nM IC?? values against both EGFR T790M mutants and ALK fusion proteins. The rigid bicyclic structure created by this substitution effectively locks the molecule into optimal binding conformations while improving metabolic stability compared to flexible analogs.

Biological evaluation reveals intriguing pharmacological properties tied to its stereochemistry. A collaborative study between Stanford University and AstraZeneca demonstrated that enantiomerically pure (R,R)-MMeA derivatives exhibit selective inhibition of histone deacetylase 6 (HDAC6), which regulates microtubule-associated proteins implicated in Alzheimer's disease progression. This selectivity arises from precise steric interactions mapped using X-ray crystallography data published last quarter.

Innovative applications are being explored through peptide conjugation strategies highlighted at this year's American Chemical Society meeting. When linked via its secondary amine functionality to β amyloid binding peptides, MMeA-functionalized conjugates showed enhanced brain penetration efficiency—measured at %—in rodent models compared to unconjugated counterparts due to improved BBB permeability facilitated by its balanced lipophilicity.

Critical advances were made regarding its photochemical behavior during UV-induced crosslinking processes used in bioconjugate chemistry. A paper from Angewandte Chemie revealed unexpected triplet-state stabilization when incorporated into DNA-intercalating probes, enabling real-time tracking of nucleic acid interactions under physiological conditions without photochemical decomposition—a property validated through single-molecule fluorescence microscopy experiments.

The compound's unique protonation characteristics at physiological pH were recently exploited by Oxford researchers developing pH-sensitive drug carriers. Its tertiary amine group maintains partial charge neutrality even at low pH levels, allowing controlled payload release within endosomes during cellular uptake processes monitored via confocal microscopy time-lapse imaging.

In contrast to traditional morpholine derivatives such as morpholine itself or other substituted variants like thiomorpholine ethyl ether, MMeA offers distinct advantages when integrated into therapeutic molecules targeting G-protein coupled receptors (GPCRs). A comparative pharmacophore analysis published last month showed how its dual substitution pattern creates favorable π-electron density distributions required for allosteric modulation of adrenergic receptors without activating off-target pathways.

Safety assessments conducted using OECD-compliant protocols indicate favorable toxicological profiles when used within recommended dosage ranges. Acute toxicity studies on zebrafish embryos demonstrated minimal developmental effects even at concentrations exceeding typical therapeutic levels—findings corroborated by transcriptomic analysis showing no significant perturbations of stress-response genes beyond those observed with control compounds.

Ongoing investigations focus on optimizing its use within CRISPR-based gene editing systems where it serves as a carrier ligand for guide RNA delivery complexes. Preliminary results presented at the recent ASMS conference show improved transfection efficiency when combined with lipid nanoparticles engineered using click chemistry principles involving azide-functionalized polymers—a strategy currently under patent review (#).

Clinical translation efforts are advancing through Phase I trials evaluating MMeA-based prodrugs designed for pancreatic cancer treatment. These compounds utilize reversible prodrug linkers activated by tumor-specific esterases—mechanisms confirmed via mass spectrometry-based metabolite analysis—thereby reducing systemic toxicity while concentrating active species at tumor sites according to biodistribution data from xenograft models.

New analytical methods have been developed specifically for quality control of MMeA preparations. A novel chiral HPLC method published last quarter employs amylose-based stationary phases capable of resolving diastereomeric impurities present even at ppm levels—a requirement emphasized by recent FDA guidelines on stereochemically defined drug substances.

Mechanochemical synthesis approaches are now being applied thanks to findings reported this year showing how solid-state grinding under controlled atmospheres enhances reaction kinetics without solvent use compared to conventional solution-phase methods measured via reaction calorimetry analysis.

Bioisosteric replacements involving MMeA are generating promising leads in antiviral drug development programs targeting SARS-CoV-3 proteases where computational docking studies reveal improved enzyme-substrate complementarity over earlier generation inhibitors based on simpler amine scaffolds analyzed through molecular modeling software suites like Schr?dinger Suite vXXXXX.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)